Q-omics provides the consensus-scored HDGFP1 profile across patient tissues and cancer cell-line models. HDGFP1 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, HDGFP1 is differentially expressed in 5, with the highest sampling consensus in STAD. Additionally, HDGFP1 RNA expression shows 6,198 significant protein co-abundance associations, with the highest sampling consensus in BRCA. Together, these results highlight LIHC, STAD, and BRCA as cancer lineages where HDGFP1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HDGFP1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HDGFP1 survival associations across molecular data types. HDGFP1 RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HDGFP1 RNA expression–survival associations across cancer types. High HDGFP1 expression shows unfavorable associations in LIHC, BLCA and CHOL, but favorable associations in HNSC, READ and KIRC. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify LIHC as the clearest survival context for HDGFP1 RNA expression.
This table summarizes HDGFP1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for HDGFP1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HDGFP1 shows lower tumor expression in KICH and higher tumor expression in STAD, BRCA, LUSC and LIHC. The STAD box plot shows higher HDGFP1 RNA expression in tumor versus normal tissue (log2 FC = +0.614, t-test p = .004).
This table shows molecular features associated with HDGFP1 in patient tissues and cancer cell lines. In patient samples, HDGFP1 shows the broadest associations at the RNA and protein expression levels, with BRCA recurring as the lineage with the largest associated feature set.
